Literature DB >> 12642009

Angiotensin and insulin resistance: conspiracy theory.

Raymond R Townsend1.   

Abstract

Resistance to the metabolic effects of insulin is a contender for the short list of major cardiovascular risk factors. Since the elements of the syndrome of insulin resistance were first articulated together in 1988, numerous epidemiologic investigations and treatment endeavors have established a relationship between the metabolic disarray of impaired insulin action and cardiovascular disease. Angiotensin II, the primary effector of the renin-angiotensin system, has also achieved a place in the chronicles of cardiovascular risk factors. Conspiracy mechanisms by which angiotensin II and insulin resistance interact in the pathogenesis of cardiovascular disease are reviewed, with particular attention to recent developments in this engaging area of human research.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12642009     DOI: 10.1007/s11906-003-0066-1

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  40 in total

1.  PLASMA-INSULIN CONCENTRATIONS AFTER MYOCARDIAL INFRACTION.

Authors:  N PETERS; C N HALES
Journal:  Lancet       Date:  1965-05-29       Impact factor: 79.321

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Comparison of haemodynamic effects of equipressor doses of intravenous angiotensin and noradrenaline in man.

Authors:  J Brod; Z Hejl; A Hornych; J Jirka; V Slechta; B Buriánová
Journal:  Clin Sci       Date:  1969-04       Impact factor: 6.124

4.  The effect of Losartan on insulin resistance and beta cell function in chronic hemodialysis patients.

Authors:  S Fishman; M J Rapoport; J Weissgarten; R Zaidenstein; V Dishi; I Hartzeanu; A Golik
Journal:  Ren Fail       Date:  2001-09       Impact factor: 2.606

5.  Effects of enalapril on the vascular wall in an experimental model of syndrome X.

Authors:  Roberto Miatello; Norma Risler; Susana Gonzalez; Claudia Castro; Mariel Rüttler; Montserrat Cruzado
Journal:  Am J Hypertens       Date:  2002-10       Impact factor: 2.689

Review 6.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes.

Authors:  Joseph L Evans; Ira D Goldfine; Betty A Maddux; Gerold M Grodsky
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

7.  Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension.

Authors:  M Hanefeld; C Abletshauser
Journal:  J Int Med Res       Date:  2001 Jul-Aug       Impact factor: 1.671

8.  PAI-1 in human hypertension: relation to hypertensive groups.

Authors:  Nadarajah Srikumar; Nancy J Brown; Paul N Hopkins; Xavier Jeunemaitre; Steven C Hunt; Douglas E Vaughan; Gordon H Williams
Journal:  Am J Hypertens       Date:  2002-08       Impact factor: 2.689

Review 9.  Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition.

Authors:  E Ferrannini; G Seghieri; E Muscelli
Journal:  J Cardiovasc Pharmacol       Date:  1994       Impact factor: 3.105

10.  Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms.

Authors:  G Nickenig; J Röling; K Strehlow; P Schnabel; M Böhm
Journal:  Circulation       Date:  1998-12-01       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.